Background Rifabutin, an oral drug approved to treat Mycobacterium avium infections,
demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium …

Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii. We sought to
characterize potential interactions between rifabutin and colistin, the last-resort drug for …

Acinetobacter baumannii has among the highest rates of antibiotic resistance encountered
in hospitals. New therapies are critically needed. We found that rifabutin has previously …

Rifamycin antibiotics were discovered during the 1950s, and their main representative,
rifampicin, remains a cornerstone treatment for TB. The clinical use of rifamycin is restricted …

Acinetobacter baumannii is a gram-negative bacterium causing severe hospital-acquired
infections such as bloodstream infections or pneumonia. Moreover, multidrug resistant A …

We recently reported that the antimicrobial activity of rifabutin against Acinetobacter
baumannii is best modeled by the use of RPMI for in vitro susceptibility testing. Here, we …

The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter
baumannii with emerging cefiderocol resistance remains challenging and unclear. We …

Synopsis Rifabutin is a derivative of rifamycin S with activity against mycobacteria including
atypical organisms such as Mycobacterium avium and M. intracellulare, also referred to as …

Objective The rising occurrence of drug-resistant pathogens accentuates the need to identify
novel antibiotics. We wanted to identify new scaffolds for drug discovery by repurposing FDA …

Rifabutin is a spiro-piperidyl-rifamycin structurally closely related to rifampicin that shares
many of its properties. We attempted to address the reasons why this drug, which was …